The abstract is read at the publisher; the summary is JClub's.
Once-weekly subcutaneous ribupatide in adults in China with overweight or obesity without diabetes produced greater week-48 weight loss than placebo, reaching -17.7% with 6 mg.
- Why it matters: Obesity remains a major health problem in China, and more options are needed for long-term weight management in people without diabetes.
- What they did: In a phase 3, multicenter, randomized, double-blind trial at 55 sites, 567 participants received ribupatide 2 mg, 4 mg, or 6 mg or placebo for 48 weeks with dose escalation and lifestyle intervention.
- The result: At week 48, placebo-adjusted differences in percent body-weight change were -9.3, -15.0, and -16.3 percentage points for 2, 4, and 6 mg (all P<.001), with ≥5% loss in 68.1%, 88.0%, and 85.7% vs 16.0% on placebo; gastrointestinal events were most common.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.